Summary of Study ST002924

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001816. The data can be accessed directly via it's Project DOI: 10.21228/M8ZX5S This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST002924
Study TitleGut sphingolipid metabolites in infants with atopic dermatitis associated with food allergy - Part 2
Study SummaryThis study determines sphingolipids and diacylglycerols from infant feces to explore the lipid changes with food allergy in atopic dermatitis. Food allergy (FA) may be present in the range of 20–80% in atopic dermatitis (AD). Food sensitization through the skin can cause FA due to damage to the skin barrier, and failure to acquire tolerance to food allergens in the gut can equally cause the development of FA. Gut metabolites can influence the physical gut barrier and intestinal homeostasis. Therefore, it is possible that gut metabolites related to gut immunity play an important role in the development of FA. Sphingolipids are key factors in cell inflammatory response and affect gut epithelial cells and skin barrier integrity and function. FA is associated with a marked decrease in serum sphingolipid levels. However, there are no reports of FA-associated gut sphingolipid metabolites in infants by targeted metabolomics. In our previous study, we showed that when FA is present in various phenotypes of AD in early life, it might be associated with the later development of asthma. The discovery of a biomarker that can distinguish the phenotypes that accompany AD and FA from other AD phenotypes is therefore expedient. Consequently, we aimed to investigate whether FA in AD infants. can be classified as gut sphingolipid metabolites using targeted metabolomics.
Institute
Asan Medical Center
Last NameYoo
First NameHyun Ju
Address88, Olympic-ro, 43-gil, Songpa-gu, Seoul, Seoul, 05505, Korea, South
Emailyoohyunju@amc.seoul.kr
Phone02-3010-4029
Submit Date2023-10-07
Raw Data AvailableYes
Raw Data File Type(s)rdb
Analysis Type DetailLC-MS
Release Date2023-11-01
Release Version1
Hyun Ju Yoo Hyun Ju Yoo
https://dx.doi.org/10.21228/M8ZX5S
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR001816
Project DOI:doi: 10.21228/M8ZX5S
Project Title:Gut sphingolipid metabolites in infants with atopic dermatitis associated with food allergy
Project Summary:This study determines S1P, ceradmides, sphingomyelins and diacylglycerols from infant feces to explore differential sphingolipid metabolism associated with food allergy in atopic dermatitis.
Institute:Asan Medical Center
Last Name:Yoo
First Name:Hyun Ju
Address:88, Olympic-ro, 43-gil, Songpa-gu, Seoul, Seoul, 05505, Korea, South
Email:yoohyunju@amc.seoul.kr
Phone:02-3010-4029

Subject:

Subject ID:SU003037
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Gender:Not applicable
Human Race:Pacific asian

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Factor
SA317554d_AD_12AD
SA317555d_AD_10AD
SA317556d_AD_13AD
SA317557d_AD_15AD
SA317558d_AD_16AD
SA317559d_AD_9AD
SA317560d_AD_14AD
SA317561d_AD_7AD
SA317562d_AD_3AD
SA317563d_AD_2AD
SA317564d_AD_4AD
SA317565d_AD_5AD
SA317566d_AD_11AD
SA317567d_AD_6AD
SA317568d_AD_8AD
SA317569d_AD_17AD
SA317570d_AD_26AD
SA317571d_AD_25AD
SA317572d_AD_27AD
SA317573d_AD_28AD
SA317574d_AD_30AD
SA317575d_AD_29AD
SA317576d_AD_24AD
SA317577d_AD_23AD
SA317578d_AD_19AD
SA317579d_AD_18AD
SA317580d_AD_20AD
SA317581d_AD_21AD
SA317582d_AD_22AD
SA317583s_AD_1AD
SA317584d_AD_1AD
SA317585s_AD_21AD
SA317586s_AD_22AD
SA317587s_AD_20AD
SA317588s_AD_19AD
SA317589s_AD_17AD
SA317590s_AD_18AD
SA317591s_AD_23AD
SA317592s_AD_24AD
SA317593s_AD_28AD
SA317594s_AD_29AD
SA317595s_AD_27AD
SA317596s_AD_26AD
SA317597s_AD_25AD
SA317598s_AD_16AD
SA317599s_AD_15AD
SA317600s_AD_5AD
SA317601s_AD_6AD
SA317602s_AD_4AD
SA317603s_AD_3AD
SA317604s_AD_2AD
SA317605s_AD_7AD
SA317606s_AD_8AD
SA317607s_AD_13AD
SA317608s_AD_14AD
SA317609s_AD_12AD
SA317610s_AD_10AD
SA317611s_AD_9AD
SA317612s_AD_30AD
SA317613s_AD_11AD
SA317614d_AD_FA_57AD_FA
SA317615d_AD_FA_56AD_FA
SA317616d_AD_FA_58AD_FA
SA317617d_AD_FA_59AD_FA
SA317618d_AD_FA_60AD_FA
SA317619d_AD_FA_55AD_FA
SA317620d_AD_FA_54AD_FA
SA317621d_AD_FA_50AD_FA
SA317622d_AD_FA_49AD_FA
SA317623d_AD_FA_51AD_FA
SA317624d_AD_FA_52AD_FA
SA317625d_AD_FA_53AD_FA
SA317626d_AD_FA_61AD_FA
SA317627d_AD_FA_62AD_FA
SA317628d_AD_FA_70AD_FA
SA317629d_AD_FA_69AD_FA
SA317630d_AD_FA_71AD_FA
SA317631d_AD_FA_72AD_FA
SA317632d_AD_FA_73AD_FA
SA317633d_AD_FA_68AD_FA
SA317634d_AD_FA_67AD_FA
SA317635d_AD_FA_63AD_FA
SA317636d_AD_FA_64AD_FA
SA317637d_AD_FA_65AD_FA
SA317638d_AD_FA_66AD_FA
SA317639d_AD_FA_48AD_FA
SA317640d_AD_FA_47AD_FA
SA317641s_AD_FA_59AD_FA
SA317642s_AD_FA_45AD_FA
SA317643s_AD_FA_58AD_FA
SA317644s_AD_FA_57AD_FA
SA317645s_AD_FA_56AD_FA
SA317646s_AD_FA_60AD_FA
SA317647s_AD_FA_61AD_FA
SA317648s_AD_FA_65AD_FA
SA317649s_AD_FA_66AD_FA
SA317650s_AD_FA_64AD_FA
SA317651s_AD_FA_63AD_FA
SA317652s_AD_FA_62AD_FA
SA317653s_AD_FA_55AD_FA
Showing page 1 of 4     Results:    1  2  3  4  Next     Showing results 1 to 100 of 318

Collection:

Collection ID:CO003030
Collection Summary:The study population consisted of 158 six-month-old infants (46 healthy infants, 30 only AD group, and 82 with combined AD and FA) involved in the Cohort for Childhood Origin of Asthma and Allergic Diseases (COCOA) (reference: BMC Pulm Med 2014, 14:109.)
Sample Type:Feces

Treatment:

Treatment ID:TR003046
Treatment Summary:no treatment

Sample Preparation:

Sampleprep ID:SP003043
Sampleprep Summary:~40 mg of feces was used and lipids were extracted by Bligh and Dyer method after adding internal standard solutions (50 μl of 100 nM C18 ceramide-d7 and C18:1 Sphingomyelin-d9 and 200 μl of 1 μM 1,3-19:0-d5). Organic solutions containing the lipids were dried using a vacuum centrifuge and stored at –20°C until LC-MS/MS analysis. The dried matter was reconstituted with methanol and injected into the LC-MS/MS system.

Combined analysis:

Analysis ID AN004794 AN004795
Analysis type MS MS
Chromatography type Reversed phase Reversed phase
Chromatography system Agilent 1290 Infinity Agilent 1290 Infinity
Column Agilent Pursuit 5 C18 (150 x 2.0 mm, 5um) Agilent Pursuit 5 C18 (150 x 2.0 mm, 5um)
MS Type ESI ESI
MS instrument type QTRAP QTRAP
MS instrument name ABI Sciex 5500 QTrap ABI Sciex 5500 QTrap
Ion Mode POSITIVE POSITIVE
Units pmol/mg pmol/mg

Chromatography:

Chromatography ID:CH003625
Chromatography Summary:Ceramides, sphingomyelines, sphinganine, sphingosine
Instrument Name:Agilent 1290 Infinity
Column Name:Agilent Pursuit 5 C18 (150 x 2.0 mm, 5um)
Column Temperature:35
Flow Gradient:50 % of B at 0 min, 50 % of B for 5 min, 50-70 % of B for 3 min, 70 % of B for 7 min, 70-90 % of B for 7 min, 90 % of B for 3 min, 90-50 % of B for 0.1 min, 50 % of B for 4.9 min
Flow Rate:200 uL/min
Solvent A:5 mM ammonium formate/MeOH/tetrahydrofuran (500/200/300, v/v/v)
Solvent B:5 mM ammonium formate/MeOH/ tetrahydrofuran (100/200/700, v/v/v)
Chromatography Type:Reversed phase
  
Chromatography ID:CH003626
Chromatography Summary:diacylglycerols
Instrument Name:Agilent 1290 Infinity
Column Name:Agilent Pursuit 5 C18 (150 x 2.0 mm, 5um)
Column Temperature:35
Flow Gradient:90 % of B for 0 min, 90 % of B for 6 min, 90 to 95 % of B for 0.6 min, 95 % of B for 3.4 min, 95 to 90 % of B for 0.1 min, and 90 % of B for 1.9 min
Flow Rate:200 uL/min
Solvent A:5 mM ammonium formate/MeOH/tetrahydrofuran (500/200/300, v/v/v)
Solvent B:5 mM ammonium formate/MeOH/ tetrahydrofuran (100/200/700, v/v/v)
Chromatography Type:Reversed phase

MS:

MS ID:MS004540
Analysis ID:AN004794
Instrument Name:ABI Sciex 5500 QTrap
Instrument Type:QTRAP
MS Type:ESI
MS Comments:Multiple reaction monitoring (MRM) was performed in the positive ion mode and the extracted ion chromatogram corresponding to the specific transition for each lipid was used for quantification. The calibration range for each lipid was 0.1-1000 nM (r2 ≥ 0.99). Data analysis was performed by using Analyst 1.5.2 software.
Ion Mode:POSITIVE
Acquisition Parameters File:MS_metadata.docx
  
MS ID:MS004541
Analysis ID:AN004795
Instrument Name:ABI Sciex 5500 QTrap
Instrument Type:QTRAP
MS Type:ESI
MS Comments:Multiple reaction monitoring (MRM) was performed in the positive ion mode and the extracted ion chromatogram corresponding to the specific transition for each lipid was used for quantification. The calibration range for each lipid was 0.1-1000 nM (r2 ≥ 0.99). Data analysis was performed by using Analyst 1.5.2 software.
Ion Mode:POSITIVE
Acquisition Parameters File:MS_metadata.docx
  logo